natgillin/translations-raw huggingface dataset:
Results from the long-term cardiovascular outcome study with 4949 patients randomised to dulaglutide and followed for a median of 5.4 years were consistent with these findings. 
Rezultati dolgotrajne študije preizkušanja kardiovaskularnih izzidov v kateri je bilo randomizirano 4949 bolnikov na dulaglutid in spremljano v povprečju 5,4 let so bili skladni s temi ugotovitvami.
Your doctor, pharmacist or nurse can help you choose the injection site that is best for you. 
• Zdravnik, farmacevt ali medicinska sestra vam lahko pomagajo izbrati mesto injiciranja, ki je najbolj ustrezno za vas.
Do I need to hold the injection button down until the injection is complete? 
Ali moram držati gumb za injiciranje, dokler injiciranje ni končano?
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications 
• v obliki monoterapije, kadar metformin šteje za neustreznega zaradi neprenašanja ali kontraindikacij,
the label to make sure you have the correct medicine and it has not expired. 
oznako, da se boste prepričali, da imate pravo zdravilo in da se rok njegove uporabe ni iztekel.
That is the normal operation of the pen. 
To je normalno delovanje peresnika.
Week 1 Week 2 
1. teden 2. teden
Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. 
Sladkorna bolezen tipa 2 je stanje, pri katerem telo ne proizvaja dovolj insulina ali pa insulin, ki ga vaše telo proizvede, ne deluje tako dobro, kot bi moral.
3 PRESS AND HOLD 
3 PRITISNITE IN DRŽITE
These engineering features result in a soluble formulation and a prolonged half-life of 4.7 days, which makes it suitable for once-weekly subcutaneous administration. 
Zaradi teh tehnoloških značilnosti ima topno obliko in podaljšan razpolovni čas 4,7 dni, zaradi česar je primeren za subkutano apliciranje enkrat na teden.
Mark the day of the week you want to use your medicine to help you remember. 
Označite dan v tednu, ko želite uporabiti zdravilo, da ne boste pozabili.
CHOOSE YOUR INJECTION SITE 
IZBERITE SVOJE MESTO INJICIRANJA
Meta-analysis of phase II and III studies 
Metaanaliza študij 2. in 3. faze
The European Medicines Agency has deferred the obligation to submit the results of studies with Trulicity in one or more subsets of the paediatric population for the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odložila zahtevo za predložitev rezultatov študij z zdravilom Trulicity v eni ali več podskupinah pediatrične populacije pri zdravljenju sladkorne bolezni tipa 2 (glejte poglavje 4.2 za informacije o uporabi pri otrocih).
Insert the needle into your skin at about a 45-degree angle. 
Vstavite iglo v kožo pod kotom približno 45 stopinj.
Elderly No dose adjustment is required based on age (see section 5.2). 
Starejši Prilagoditev odmerka na osnovi starosti ni potrebna (glejte poglavje 5.2).
Discontinuation due to an adverse event 
Prekinitve zdravljenja zaradi neželenega dogodka
Glass syringe (type I). 
Steklena brizga (tip I).
STORAGE AND HANDLING 
RAVNANJE IN SHRANJEVANJE
Trulicity is not recommended for children and adolescents under 18 years of age because it has not been studied in these patients. 
Otroci in mladostniki Uporaba zdravila Trulicity pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva, saj pri teh bolnikih ni bila preučena.
Postprandial glucose 
Postprandialna glukoza
The safety profile of Trulicity in patients with renal impairment was similar to that observed in other studies with Trulicity. 
Varnostni profil zdravila Trulicity je pri bolnikih z okvarjenim delovanjem ledvic podoben tistemu, ki so ga opazili v drugih študijah z zdravilom Trulicity.
OTHER SPECIAL WARNING(S), IF NECESSARY If seal is broken before first use, contact pharmacist. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Če je pred prvo uporabo pečat poškodovan, se obrnite na farmacevta.
Dulaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. 
Dulaglutid se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 ali za zdravljenje diabetične ketoacidoze.
The following adverse reactions have been identified based on evaluation of the full duration of the phase II and phase III clinical studies, the long-term cardiovascular outcome study and post-marketing reports. 
Naslednje neželene učinke so odkrili na podlagi evalvacije skupnega trajanja kliničnih študij 2. in 3. faze, dolgoročne študije kardiovaskularnih izidov in poročil v obdobju trženja.
SCAN THIS CODE TO LAUNCH www.trulicity.eu 
SKENIRAJTE TO KODO ZA ZAGON www.trulicity.eu
The mean age was 66.2 years, the mean BMI was 32.3 kg/m², and 46.3 % of patients were female. 
Povprečna starost je bila 66,2 leta, povprečni ITM 32,3 kg/m² in 46,3 % bolnikov je bilo ženskega spola.
The directions regarding syringe handling and disposal are not intended to replace local or institutional policies. 
• Navodila za ravnanje z injekcijskimi brizgami in za njihovo odlaganje niso namenjena temu, da bi nadomestila lokalne smernice ali smernice zdravstvenih ustanov.
Component of a multipack, can't be sold separately. 
Sestavnih delov večjega pakiranja ni mogoče prodajati ločeno.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN PROIZVAJALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
It is important to continue to follow the advice on diet and exercise given to you by your doctor, pharmacist or nurse. 
Pomembno je, da še naprej upoštevate nasvete o dieti in telesni vadbi, ki vam jih je dal vaš zdravnik, farmacevt ali medicinska sestra.
Your doctor may want to lower the dose of these other medicines to prevent you from getting low blood sugar levels (hypoglycaemia). 
Vaš zdravnik bo morda želel zmanjšati odmerek teh drugih zdravil, da bo preprečil pojav nizkih ravni krvnega sladkorja pri vas (hipoglikemija).
What if the needle looks bent? 
Kaj če je igla videti ukrivljena?
If you stop using Trulicity, your blood sugar levels can increase. 
Če prenehate uporabljati zdravilo Trulicity, lahko ravni vašega krvnega sladkorja narastejo.
The majority of the effect on fasting blood glucose concentrations occurred by 2 weeks. 
Večina učinkov na koncentracije krvne glukoze na tešče je nastopila v prvih 2 tednih.
They are most common when first starting dulaglutide but decrease over time in most patients. 
Najpogostejši so ob začetku jemanja dulaglutida, vendar pri večini bolnikov postopoma izginejo.
Reduction in body weight was observed in patients treated with dulaglutide irrespective of nausea, though the reduction was numerically larger in the group with nausea. 
Zmanjšanje telesne mase so opazili pri bolnikih, zdravljenih z dulaglutidom, ne glede na slabost, čeprav je bilo zmanjšanje številčno večje v skupini s slabostjo.
Please keep this in mind in all situations where you might put yourself and others at risk (e.g. driving a car or using machines). 
V vseh okoliščinah, kjer bi lahko ogrozili sebe ali druge (npr. pri vožnji ali upravljanju strojev), imejte v mislih, da lahko pride do te težave.
The increased exposure may enhance the effects of dulaglutide on blood glucose levels. 
Povečana izpostavljenost lahko okrepi učinke dulaglutida na ravni krvne glukoze.
- you are on dialysis as this medicine is not recommended. 
- ste na dializi, ker se uporabe tega zdravila v tem primeru ne priporoča.
If you drop it on a hard surface, do not use it. 
Če vam pade na trdo podlago, ga ne uporabite.
Trulicity was superior in preventing MACE compared to placebo (Figure 1). 
Zdravilo Trulicity je bilo superiorno pri preprečevanju MACE v primerjavi s placebom (slika 1).
However, for patients receiving oral medicinal products requiring rapid gastrointestinal absorption or prolonged release formulations the potential for altered drug exposure should be considered. 
Toda pri bolnikih, ki prejemajo zdravila za peroralno uporabo, ki zahtevajo hitro absorpcijo v prebavilih ali zdravila s podaljšanim sproščanjem, je treba upoštevati možnost spremenjene izpostavljenosti zdravilu.
Native GLP-1 has a half-life of 1.5-2 minutes due to degradation by DPP-4 and renal clearance. 
Naravni GLP-1 ima razpolovni čas 1,5-2 minuti zaradi razgradnje z DPP-4 in ledvičnega očistka.
What Trulicity is and what it is used for 
Kaj je zdravilo Trulicity in za kaj ga uporabljamo
You should see a doctor immediately if you experience symptoms such as rashes, itching and rapid swelling of the tissues of the neck, face, mouth or throat, hives and difficulties breathing. 
Takoj morate obiskati zdravnika, če se pri vas pojavijo simptomi, kot so: izpuščaj, srbečica in hitro otekanje tkiva vratu, obraza, ust ali grla, koprivnica in težave z dihanjem.
Cardiovascular outcome study 
Študija kardiovaskularnih izidov
In contrast to native GLP-1, dulaglutide is resistant to degradation by DPP-4, and has a large size that slows absorption and reduces renal clearance. 
Vendar pa je za razliko od naravnega GLP-1 dulaglutid stabilen proti razgradnji z DPP-4 , in ima večjo velikost, ki upočasni absorpcijo ter zmanjša ledvični očistek.
Inject your next dose on your regular scheduled day. 
Svoj naslednji odmerek si injicirajte na naslednji predpisani dan.
Injection site adverse events were reported in 1.9 % of patients receiving dulaglutide. 
O reakcijah na mestu injiciranja so poročali pri 1,9 % bolnikov, ki so prejemali dulaglutid.
Sitagliptin can produce up to 80 % inhibition of DPP-4 over a 24-hour period. 
Sitagliptin lahko povzroči do 80% zaviranje dipeptidil-peptidaze 4 (DPP-4) v 24-urnem obdobju.
Do not remove the pen from your skin until you hear the second louder click. 
Ne umaknite peresnika s kože, dokler ne slišite drugega glasnega klika.
Your doctor should tell you how to treat low blood sugar. 
Vaš zdravnik vam bo razložil, kako uravnati nizek krvni sladkor.
• When you press the green injection button, the pen will automatically insert the needle into your skin, inject the medicine, and pull back (retract) the needle after the injection is complete. 
• Ko pritisnete zeleni gumb za injiciranje, bo peresnik samodejno potisnil iglo v vašo kožo, injiciral zdravilo in iglo po zaključenem injiciranju potegnil nazaj.
Trulicity that has been frozen must not be used. 
Zdravila Trulicity, ki je zmrznilo, ne smete uporabljati.
- Symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, feeling hungry, confusion, irritability, fast heartbeat and sweating. 
- simptomi nizkega krvnega sladkorja lahko vključujejo glavobol, zaspanost, šibkost, omotico, občutek lakote, zmedenost, razdražljivost, hiter srčni utrip in potenje.
Manufacturer Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italy 
Proizvajalec Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italija
This occurs when the needle starts retracting in about 5-10 seconds. 
Do tega pride, ko se igla začne umikati, po približno 5
What Trulicity is and what it is used for What you need to know before you use Trulicity How to use Trulicity 
Kaj je zdravilo Trulicity in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Trulicity Kako uporabljati zdravilo Trulicity
What if I unlock the pen and press the green injection button before pulling off the base cap? 
Kaj če odklenem peresnik in pritisnem zeleni gumb za injiciranje preden odstranim pokrovček z dna?
Continue holding the clear base firmly against your skin until you hear a second click. 
Še naprej trdno držite prozorno podnožje na koži, dokler ne zaslišite drugega klika.
It is important that you test your blood glucose levels as instructed by your doctor, pharmacist or nurse, if you are taking Trulicity with a sulphonylurea or insulin. 
Pomembno je, da redno preverjate vaše ravni glukoze v krvi kot vam je naročil zdravnik, farmacevt ali medicinska sestra, če jemljete zdravilo Trulicity s sulfonilsečnino ali z insulinom.
BEFORE YOU GET STARTED Remove 
PREDEN ZAČNETE
Change (rotate) your injection site each week. 
• Vsak teden spremenite (rotirajte) mesto injiciranja.
• When refrigeration is not possible, you can keep your syringe at room temperature 
• Kadar shranjevanje v hladilniku ni mogoče, lahko svoj peresnik shranjujete pri sobni temperaturi (pod
Tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby, as Trulicity should not be used during pregnancy. 
Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, saj zdravila Trulicity med nosečnostjo ne smete jemati.
This clinical study did not include patients with end stage renal disease. 
Ta klinična študija ni vključevala bolnikov s končno ledvično odpovedjo.
Do not remove the base cap and do not use the pen. 
Ne odstranjujte pokrovčka z dna in ne uporabite peresnika.
Consistent with the pharmacokinetic profile, dulaglutide has a pharmacodynamic profile suitable for once weekly administration (see section 5.2). 
Skladno s farmakokinetičnim profilom ima dulaglutid farmakodinamični profil, ki je primeren za aplikacijo zdravila enkrat na teden (glejte poglavje 5.2).
Clinical studies with dulaglutide have indicated enhanced beta-cell function as measured by homeostasis model assessment (HOMA2-%B). 
Klinične študije z dulaglutidom so pokazale povečano delovanje beta celic, merjeno z oceno modela homeostaze (HOMA2-%B).
If you want to do so, you can use the same area of your body each week. 
Če želite, lahko vsak teden uporabite isti del telesa za injiciranje.
Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. 
Dulaglutid je dolgodelujoči receptorski agonist glukagonu podobnega peptida 1 (GLP-1).
The molecule consists of 2 identical disulfide-linked chains, each containing a modified human GLP-1 analogue sequence covalently linked to a modified human immunoglobulin G4 (IgG4) heavy chain fragment (Fc) by a small peptide linker. 
Molekula je sestavljena iz 2 identičnih verig, povezanih z disulfidno vezjo, vsaka veriga pa vsebuje modificiran analogni niz humanega GLP-1, kovalentno spojen v modificirani del težke verige (Fc) področja humanega imunoglobulina G4 (IgG4) z majhno peptidno vezjo.
Trulicity contains an active substance called dulaglutide and is used to lower blood sugar (glucose) in adults with type 2 diabetes mellitus and can help prevent heart disease. 
Zdravilo Trulicity vsebuje zdravilno učinkovino, imenovano dulaglutid, in se uporablja za zniževanje krvnega sladkorja (glukoze) pri odraslih s sladkorno boleznijo tipa 2 ter lahko pomaga preprečevati bolezni srca.
The signs include rapid weight loss, feeling sick or being sick, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat. 
Znaki vključujejo hitro izgubo telesne mase, občutek slabosti ali siljenje na bruhanje, sladkoben vonj vaše sape, sladek ali kovinski okus v vaših ustih ali spremenjen vonj vašega urina ali znoja.
The Trulicity long-term cardiovascular outcome study was a placebo-controlled, double-blind clinical trial. 
Dolgoročna študija kardiovaskularnih izidov z zdravilom Trulicity je bila s placebom nadzorovano, dvojno slepo klinično preskušanje.
Dulaglutide is associated with mean increases from baseline in pancreatic enzymes (lipase and/or pancreatic amylase) of 11 % to 21 % (see section 4.4). 
Dulaglutid je povezan s povprečnim zvišanjem encimov trebušne slinavke od izhodišča (lipaza in/ali pankreasna amilaza) od 11 % do 21 % (glejte poglavje 4.4).
- you have ever had pancreatitis (inflammation of the pancreas) which causes severe pain in the stomach and back which does not go away. 
- ste kadar koli imeli pankreatitis (vnetje trebušne slinavke), ki povzroča hudo bolečino v trebuhu in hrbtu, ki ne poneha.
This change is not expected to have clinical consequences. 
Ni verjetno, da bi imela ta sprememba klinične posledice.
Following subcutaneous administration to patients with type 2 diabetes, dulaglutide reaches peak plasma concentrations in 48 hours. 
Absorpcija Po subkutani aplikaciji bolnikom s sladkorno boleznijo tipa 2 dulaglutid doseže najvišje koncentracije v plazmi v 48 urah.
- you have diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin). 
- imate diabetično ketoacidozo (zaplet sladkorne bolezni, do katerega pride, ko telo ne more razgraditi glukoze, ker nima na voljo dovolj insulina).
This is not unusual and will not affect your dose. 
To ni nič neobičajnega in ne bo vplivalo na vaš odmerek.
- you have type 1 diabetes (the type when your body does not produce any insulin) as this medicine may not be right for you. 
- imate sladkorno bolezen tipa 1 (tip bolezni pri kateri vaše telo sploh ne proizvaja insulina), saj to zdravilo najverjetneje ne bo pravo za vas.
When your injection is complete, the plunger should be pushed fully into the syringe, with no more medicine left in it. 
Ko je injiciranje končano, mora biti bat v celoti potisnjen v injekcijsko brizgo, v kateri ni več zdravila.
With your other hand, hold the syringe like a pencil. 
Z drugo roko primite injekcijsko brizgo kot svinčnik.
Dulaglutide significantly improved total treatment satisfaction compared to exenatide twice daily. 
Dulaglutid je značilno izboljšal skupno zadovoljstvo z zdravljenjem v primerjavi z eksenatidom dvakrat na dan.
Body weight or body mass index 
Telesna masa ali indeks telesne mase
In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis. 
Če ni drugih znakov in simptomov akutnega pankreatitisa, sama zvišanja ravni encimov trebušne slinavke ne napovedujejo akutnega pankreatitisa.
Patients with dulaglutide anti-drug antibodies generally had low titres, and although the number of patients developing dulaglutide anti-drug antibodies was low, examination of the phase III data revealed no clear impact of dulaglutide anti-drug antibodies on changes in HbA1c. 
Bolniki s protitelesi proti dulaglutidu so na splošno imeli nizke titre in čeprav je bilo število bolnikov, pri katerih so se razvila protitelesa proti dulaglutidu, majhno, je pregled podatkov 3. faze razkril, da ni jasnega vpliva protiteles proti dulaglutidu na spremembe vrednosti HbA1c.
Statistically significant delays in lisinopril tmax of approximately 1 hour were observed on Days 3 and 24 of the study. 
Opazili so statistično pomembne zakasnitve v tmax lisinoprila za približno 1 uro na dneva 3 in 24 študije.
In the presence of elevated glucose concentrations, dulaglutide increases intracellular cyclic AMP (cAMP) in pancreatic beta cells leading to insulin release. 
Pri povečanih koncentracijah glukoze dulaglutid povečuje intracelularno ciklično AMP (cAMP) v beta celicah trebušne slinavke, s čimer povzroči sproščanje insulina.
Until then, store your pen safely to avoid an accidental needle stick injury. 
Do tedaj shranite svoj peresnik na varno mesto, da boste preprečili poškodbe zaradi vboda igle.
Papendorpseweg 83, 3528 BJ Utrecht 
Papendorpseweg 83, 3528 BJ UtrechtNizozemska
It is not known if dulaglutide passes into human breast milk. 
Ni znano, ali dulaglutid prehaja v materino mleko.
- or with other medicines for diabetes when they are not enough to control your blood sugar levels. 
- ali z drugimi zdravili za zdravljenje sladkorne bolezni, če ta ne zadoščajo za uravnavanje vaših ravni krvnega sladkorja.
Slowly push the plunger all the way in until all the medicine is injected. 
Počasi potisnite bat do konca, dokler ne injicirate vsega zdravila.
Type 2 Diabetes Mellitus 
Sladkorna bolezen tipa 2
• When refrigeration is not possible, you can keep your pen at room temperature (below 30°C) for up to a total of 14 days. 
• Kadar shranjevanje v hladilniku ni mogoče, lahko svojo injekcijsko brizgo shranjujete pri sobni temperaturi (pod 30 °C) skupno največ 14 dni.
Do not use Trulicity - if you are allergic to dulaglutide or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na dulaglutid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Figure 2: Forest plot of analyses of individual cardiovascular event types, all cause death, and consistency of effect across subgroups for the primary endpoint 
Slika 2: Drevesni diagram analiz posameznih vrst kardiovaskularnih dogodkov, smrti zaradi katerega koli vzroka, in podskupin za primarni opazovani dogodek
Dulaglutide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients. 
Uporaba dulaglutida ni bila preučena pri bolnikih s hudo boleznijo prebavil, vključno s hudo gastroparezo, zato pri teh bolnikih uporaba zdravila ni priporočljiva.
The durability of effect on beta-cell function was maintained through the longest study duration of 104 weeks. 
Trajanje učinka na delovanje beta celic se je ohranilo vse do 104. tedna, kolikor je trajala najdaljša študija.
Therefore, the use of dulaglutide is not recommended during pregnancy. 
Uporaba dulaglutida med nosečnostjo zato ni priporočljiva.
Store in a refrigerator (2ºC - 8ºC). 
Shranjujte v hladilniku (2 ºC 8 ºC).
Subcutaneous use. 
subkutana uporaba.
Studies characterising the pharmacokinetics of dulaglutide in paediatric patients have not been performed. 
Pediatrična populacija Študije, ki bi ugotavljale farmakokinetiko dulaglutida pri pediatričnih bolnikih, niso bile opravljene.
In the phase II and phase III clinical studies, systemic hypersensitivity events (e.g., urticaria, edema) were reported in 0.5 % of patients receiving dulaglutide. 
V kliničnih študijah 2. in 3. faze so poročali o dogodkih sistemske preobčutljivosti (npr. urtikarija, edem) pri 0,5 % bolnikov, ki so prejemali dulaglutid.
Not known: the frequency cannot be estimated from the available data - Bowel obstruction - a severe form of constipation with additional symptoms such as stomach ache, bloating or vomiting. 
Neznani učinki: pogostnost ne more biti ocenjena iz razpoložljivih podatkov - Zapora črevesja - resna oblika zaprtosti z dodatnimi simptomi kot so bolečina v trebuhu,
Patients receiving dulaglutide in combination with sulphonylurea or insulin may have an increased risk of hypoglycaemia. 
Pri bolnikih, ki prejemajo zdravilo dulaglutid v kombinaciji s sulfonilsečnino ali insulinom, lahko obstaja povečano tveganje za hipoglikemijo.
You can use your syringe at any time of the day, with or without meals. 
Injekcijski peresnik lahko uporabljate kadar koli v dnevu, z ali brez hrane.
Gender and race Gender and race had no clinically meaningful effect on the pharmacokinetics of dulaglutide. 
Spol in rasa nista imela klinično pomembnega učinka na farmakokinetiko dulaglutida.
METHOD AND ROUTE(S) OF ADMINISTRATION For single use only. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Za enkratno uporabo.
The incidence of acute pancreatitis in Phase II and III clinical studies was 0.07% for dulaglutide compared to 0.14% for placebo and 0.19% for comparators with or without additional background antidiabetic therapy. 
Pojavnost akutnega pankreatitisa v kliničnih študijah 2. in 3. faze je bila 0,07 % za dulaglutid v primerjavi z 0,14 % za placebo in 0,19 % za primerjalna zdravila z ali brez osnovnega antidiabetičnega zdravljenja.
This leaflet was last revised in Month YYYY 
Navodilo je bilo nazadnje revidirano mesec LLLL
Cardiovascular Evaluation 
Kardiovaskularna ocena
In the completed phase II and phase III initial registration studies, 4,006 patients were exposed to dulaglutide alone or in combination with other glucose lowering medicinal products. 
Povzetek varnostnega profila V zaključenih začetnih registracijskih študijah 2. in 3. faze je bilo 4006 bolnikov izpostavljenih dulaglutidu samemu ali pa v kombinaciji z drugimi zdravili za znižanje glukoze.
Patient reported outcomes 
Izidi, o katerih so poročali bolniki
You may inject the medicine into your stomach (abdomen) or thigh. 
• Zdravilo si lahko injicirate v trebuh (abdomen) ali stegno.